当前位置:首页 > 报告详情

ADPT 2025 JPM Healthcare Conference Presentation.pdf

上传人: c** 编号:603974 2025-02-03 23页 1.71MB

1、J.P.Morgan Healthcare Conference 2025January 14th,2025 Copyright Adaptive Biotechnologies 2025.2Safe HarborThis presentation has been prepared by Adaptive Biotechnologies Corporation(“we,”“us,”“our,”“Adaptive”or the“Company”)and is made for informational purposes only.The information set forth herei

2、n does not purport to be complete or to contain all relevant information.Statements contained herein are made as of the date of this presentation unless stated otherwise.This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities,nor shall there be any s

3、ale of these securities in any jurisdiction in which such offer,solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.This presentation contains“forward-looking statements”within the meaning of Section 27A of the Securities A

4、ct of 1933,as amended,and Section 21E of the Securities Exchange Act of 1934,as amended.These statements are intended to be covered by the“safe harbor”created by those sections.Forward-looking statements are neither historical facts nor assurances of future performance.Instead,they are based on our

5、current beliefs,expectations and assumptions regarding the future of our business,future plans and strategies,our development plans,our preclinical and clinical results and other future conditions.In some cases,you can identify forward-looking statements by the following words:“may,”“will,”“could,”“

6、would,”“should,”“expect,”“intend,”“plan,”“anticipate,”“believe,”“estimate,”“predict,”“project,”“potential,”“continue,”“ongoing”or the negative of these terms or other comparable terminology,although not all forward-looking statements contain these words.All statements,other than statements of histor

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
Adaptive Biotechnologies是一家致力于基于免疫受体数据发现临床产品的公司,其业务分为诊断和药物发现两大单元。诊断业务以clonoSEQ为核心,提供血液癌变的微小残留疾病(MRD)检测,已获得FDA批准用于多发性骨髓瘤、急性淋巴细胞白血病、慢性淋巴细胞白血病和弥漫大B细胞淋巴瘤。药物发现业务专注于TCR抗原图谱绘制,开发针对自身免疫疾病和癌症的创新疗法。公司预计2024年实现30%以上的收入增长,并计划2025年实现盈利。关键数据包括:2024年预计clonoSEQ检测量增长40%,biopharma trials业务增长45%,以及实现每测试降低成本5-10个基点。此外,Adaptive正推进针对特定自身免疫疾病的抗体候选药物开发,并计划在2025年提交pre-clinical数据包。
"Adaptive Biotechnologies"的未来规划是什么? 如何看待"clonoSEQ"在血液癌诊断中的地位和前景? "Immune Medicine"业务单元的发展现状和计划是什么?
客服
商务合作
小程序
服务号
折叠